EA200800874A1 - Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия - Google Patents

Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия

Info

Publication number
EA200800874A1
EA200800874A1 EA200800874A EA200800874A EA200800874A1 EA 200800874 A1 EA200800874 A1 EA 200800874A1 EA 200800874 A EA200800874 A EA 200800874A EA 200800874 A EA200800874 A EA 200800874A EA 200800874 A1 EA200800874 A1 EA 200800874A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
selective
glu10
treatment
treatment exposure
Prior art date
Application number
EA200800874A
Other languages
English (en)
Inventor
Туэ Шварц
Пол Брайан Литтл
Ларс-Оле Герлах
Кристиан Эллинг
Original Assignee
7ТиЭм ФАРМА А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7ТиЭм ФАРМА А/С filed Critical 7ТиЭм ФАРМА А/С
Publication of EA200800874A1 publication Critical patent/EA200800874A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Пептидный агонист Y4 рецептора, выбранный из группы, состоящей из [Alа30]РР, [Thr30]PP, [Asn30]PP, [Gln30]PP, [Glu10]PP, [Glu10,Leu17,Thr30]PP, [Nle17,Nle30]PP, [Glu10,Nle17,Nle30]PP, их PPэквиваленты, и их аналоги и производные, указанные в описании, представляют собой селективные агонисты Y4 рецептора, по сравнению с Y1 и Y2 рецепторами, и применимы, например, для лечения ожирения и избыточного веса и состояний, при которых ожирение и избыточный вес рассматриваются как способствующие факторы, и для лечения диареи и кишечной гиперсекреции.
EA200800874A 2005-09-21 2005-09-21 Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия EA200800874A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010314 WO2007038942A1 (en) 2005-09-21 2005-09-21 Y4 selective receptor agonists for therapeutic interventions

Publications (1)

Publication Number Publication Date
EA200800874A1 true EA200800874A1 (ru) 2008-08-29

Family

ID=35976513

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800874A EA200800874A1 (ru) 2005-09-21 2005-09-21 Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия

Country Status (11)

Country Link
US (1) US8022035B2 (ru)
EP (1) EP1934254A1 (ru)
JP (1) JP2009508885A (ru)
CN (1) CN101268099A (ru)
AU (1) AU2005337116A1 (ru)
BR (1) BRPI0520563A2 (ru)
CA (1) CA2623088A1 (ru)
EA (1) EA200800874A1 (ru)
IL (1) IL189938A0 (ru)
NO (1) NO20081908L (ru)
WO (1) WO2007038942A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186811A1 (en) * 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
WO2005089790A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
BRPI0520566A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
US8022035B2 (en) 2005-09-21 2011-09-20 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CN101970475A (zh) * 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
TWI661835B (zh) 2013-11-15 2019-06-11 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
RU2726777C2 (ru) 2015-06-12 2020-07-15 Ново Нордиск А/С Селективные соединения пептида yy и их применения
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
JP2001505872A (ja) * 1996-09-09 2001-05-08 ジーランド ファーマシューティカルズ アクティーゼルスカブ α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
US6588708B2 (en) 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2005053726A1 (en) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
JP2007531713A (ja) 2004-03-17 2007-11-08 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
WO2005089786A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
US8022035B2 (en) 2005-09-21 2011-09-20 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
BRPI0520566A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment

Also Published As

Publication number Publication date
IL189938A0 (en) 2008-08-07
NO20081908L (no) 2008-06-20
CA2623088A1 (en) 2007-04-12
WO2007038942A1 (en) 2007-04-12
JP2009508885A (ja) 2009-03-05
CN101268099A (zh) 2008-09-17
EP1934254A1 (en) 2008-06-25
AU2005337116A1 (en) 2007-04-12
US20090118178A1 (en) 2009-05-07
BRPI0520563A2 (pt) 2009-05-19
US8022035B2 (en) 2011-09-20

Similar Documents

Publication Publication Date Title
EA200800874A1 (ru) Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
CY1118982T1 (el) Φαρμακευτικες συνθεσεις
EP2520567A3 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
EA200970051A1 (ru) Антагонист рецептора il-8
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
EA200601720A1 (ru) Селективные агонисты рецептора y4 для терапевтического воздействия
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
EA200900879A1 (ru) Пиперидиновые агонисты gpcr
WO2007050802A3 (en) Novel opioid antagonists
WO2008087491A3 (en) Method for treating or preventing symptoms of hormonal variations
DK2064348T3 (da) Profilering af receptorfamilie
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
EA200801414A1 (ru) Кальцилитические соединения
IL174762A0 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
EA200802381A1 (ru) Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
ATE421518T1 (de) Dihydrochinazolinone als 5ht-modulatoren
ATE535523T1 (de) Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten
ATE389386T1 (de) In-situ-erzeugung eines implantats für tiere
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE496049T1 (de) Als monoamin wiederaufnahmehemmer geeignete 8- azabicycloä3.2.1üoctanderivate
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
GEP20084493B (en) Kynurenic acid amide derivatives as nr2b receptor antagonists